Home / Market News / $LAKE

$LAKE news and market catalysts

The 15 most recent market catalysts affecting $LAKE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 1 high impact 11 bullish 2 bearish Biotechnology
Nov 16, 2026 Corporate Catalyst Bullish Impact 65
Lakefront Biotherapeutics Initiates New €50 Million Share Repurchase Program
Lakefront Biotherapeutics has initiated a new €50 million share repurchase program, authorizing the buyback of up to 4.6 million ordinary shares. This follows the successful comple…
Oct 28, 2026 Corporate Catalyst Neutral Impact 65
HC Wainwright Initiates Coverage on Lakewood-Amedex Biotherapeutics With Buy Rating
Investment firm HC Wainwright initiated coverage on Lakewood-Amedex Biotherapeutics Inc. with a 'Buy' rating. This is significant because analyst initiations, especially with a pos…
Oct 20, 2026 Corporate Catalyst Bullish Impact 55
Lakeland Industries' Eagle Technical Products Business Receives Two-Year Contract Cleveland Fire Brigade To Provide Protective Firefighting Gloves And Particle-Blocking Hoods
Lakeland Industries announced that its Eagle Technical Products business has been awarded a two-year contract by the Cleveland Fire Brigade in the UK. This contract is for the supp…
Oct 15, 2026 Corporate Catalyst Bullish Impact 55
Lakeland Industries Receives 3.5-Year Contract To Supply Eagle’s Ultimate Glow+ PBI Structural Firefighting Gloves To A Service In The UK; Financial Terms Not Disclosed
Lakeland Industries (LAKE) has won a 3.5-year contract to supply its specialized firefighting gloves to a UK service, following successful wearer trials. This is a positive develop…
Oct 7, 2026 Corporate Catalyst Bullish Impact 75
Lakewood-Amedex Biotherapeutics shares are trading higher after the company announced preclinical data in UTI and pulmonary infection indications in animal models treated with Bisphosphocin compounds.
The announcement of positive preclinical data for Bisphosphocin compounds in UTI and pulmonary infection indications is a significant positive catalyst for Lakewood-Amedex Biothera…
Sep 28, 2026 Corporate Catalyst Bullish Impact 75
Lakewood-Amedex Biotherapeutics shares are trading higher after the company announced Minimum Inhibitory Concentration data from recent clinical isolates for its lead clinical candidate, Nu-3.
This headline indicates a significant positive corporate catalyst for Lakewood-Amedex Biotherapeutics. Positive Minimum Inhibitory Concentration (MIC) data for a lead clinical cand…
Sep 24, 2026 Corporate Catalyst Bullish Impact 75
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed In Phase 2a Trial Of Nu-3 For Infected Diabetic Foot Ulcers; Topline Data Expected In Q1 2027
The initiation of a Phase 2a trial for Nu-3 is a critical de-risking event for Lakewood-Amedex Biotherapeutics, as it moves the drug closer to potential commercialization. Positive…
Sep 18, 2026 Corporate Catalyst Neutral Impact 75
Lakewood-Amedex Registers Resale Of Up To 4,512,400 Shares Of Common Stock By Selling Stockholder
Lakewood-Amedex is filing to register an additional 4,512,400 shares of common stock for resale by a selling stockholder. This significant increase in registrable shares stems from…
Sep 18, 2026 Corporate Catalyst Bullish Impact 75
Lakewood-Amedex Biotherapeutics Says It Obtained IRB Approvals, Site Readiness To Begin Phase 2a Trial Of Nu-3 In Infected Diabetic Foot Ulcers
This news is a significant positive catalyst for Lakewood-Amedex Biotherapeutics as it marks a crucial step forward in the development of Nu-3. Advancing to Phase 2a trials indicat…
Sep 14, 2026 Corporate Catalyst Bearish Impact 55
DA Davidson Maintains Buy on Lakeland Industries, Lowers Price Target to $15
DA Davidson analyst Michael Shlisky maintained a 'Buy' rating on Lakeland Industries but lowered the price target from $18 to $15. This action signals that while the analyst still …
Sep 9, 2026 Corporate Catalyst Bearish Impact 95
Lakeland Industries Q2 EPS $(0.50) Misses $(0.05) Estimate, Sales $50.139M Miss $51.483M Estimate
Lakeland Industries (LAKE) announced Q2 results that fell significantly short of analyst expectations, with EPS missing by a staggering 900% and sales missing by 2.61%. This substa…
Aug 31, 2026 Corporate Catalyst Bullish Impact 75
Lakewood-Amedex Biotherapeutics shares are trading higher after the company received a notice of allowance for a U.S. patent titled "ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF"
This patent allowance is a significant positive catalyst for Lakewood-Amedex, as it protects their core technology and enhances their valuation. It reduces competitive threats and …
Aug 25, 2026 Corporate Catalyst Bullish Impact 75
Lakeland Industries Announces New Contract Awards Across South America, Including Callao Fire Department Tender And Multi-Year SONDEL Utility Agreement; Terms Not Disclosed
This announcement is a significant positive catalyst for Lakeland Industries (LAKE). New contract awards, especially multi-year agreements, provide revenue visibility and demonstra…
Aug 24, 2026 Corporate Catalyst Bullish Impact 75
Lakefront Biotherapeutics Says FDA Granted Orphan Drug Designation To Gamgertamig For Treatment Of Pemphigus
The Orphan Drug Designation (ODD) granted to Gamgertamig is a significant positive catalyst for Lakefront Biotherapeutics. ODD provides incentives such as tax credits, user fee wai…
Jul 22, 2026 Corporate Catalyst Bullish Impact 75
Lakewood-Amedex Biotherapeutics shares are trading higher after the company announced resistance data for Nu-3.
The positive resistance data for Nu-3 is a significant corporate catalyst for Lakewood-Amedex, directly impacting its stock price positively. This type of data is crucial in drug d…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.